Available tests Fluorescence in situ hybridisation analysis of FFPE tissue sections for: ALK t(2p23;) rearrangement; ROS1 t(6q22;) rearrangement; MET (7q31) copy number/ratio
The determination of ALK stsus in patients with lung cancer is critical in the identification of patients eligible for ALK inhibitor therapy. Patients with ROS1 rearrangement have also been shown to be sensitive to the ALK inhibitor crizotininb, and MET amplification may contribute to acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI's), and may be a target for MET inhibitors.
Synonyms or keywords:
ALK, ROS1, MET, crizotininb, Xalkori, lung cancer, non-small cell lung cancer, adenocarcinoma, NSCLC